Inventor
MATA-FINK JORDI
US27 patents
⚠️ This page may combine multiple inventors who share the name “MATA-FINK JORDI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
RUBIUS THERAPEUTICS INC
15 patentsUS9644180B2May 9, 2017
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC98 citations98
US10344263B2Jul 9, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC14 citations94
US10329531B2Jun 25, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC18 citations94
US10253296B2Apr 9, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC16 citations94
US10301594B1May 28, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC11 citations92
US10869898B2Dec 22, 2020
Methods and compositions for immunomodulation
RUBIUS THERAPEUTICS INC6 citations84
US10557119B2Feb 11, 2020
Erythroid cells comprising phenylalanine ammonia lyase
RUBIUS THERAPEUTICS INC4 citations84
US10301593B2May 28, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC8 citations84
US10517897B1Dec 31, 2019
Methods related to engineered erythoid cells comprising 4-1BBL
RUBIUS THERAPEUTICS INC4 citations81
US10456421B2Oct 29, 2019
Compositions and methods related to engineered erythoid cells comprising 4-1BBL
RUBIUS THERAPEUTICS INC10 citations81
US10568910B2Feb 25, 2020
Compositions and methods related to engineered erythroid cells comprising IL-15
RUBIUS THERAPEUTICS INC3 citations70
US11576934B2Feb 14, 2023
Methods and compositions for immunomodulation
RUBIUS THERAPEUTICS INC0 citations62
US11554141B2Jan 17, 2023
Methods and compositions for immunomodulation
RUBIUS THERAPEUTICS INC0 citations62
US11020435B2Jun 1, 2021
Functionalized erythroid cells
RUBIUS THERAPEUTICS INC1 citations53
US10716811B2Jul 21, 2020
Compositions and methods related to multimodal therapeutic cancer indications
RUBIUS THERAPEUTICS INC0 citations49
FLAGSHIP PIONEERING INNOVATIONS V INC
7 patentsUS10683352B1Jun 16, 2020
Methods for treating cancer using GRM8 inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC20 citations91
US11034751B1Jun 15, 2021
Methods and compositions for treating cancer using serotonin receptor inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC17 citations82
US11208475B1Dec 28, 2021
Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
FLAGSHIP PIONEERING INNOVATIONS V INC3 citations70
US10457740B1Oct 29, 2019
Methods and compositions for treating cancer using P2RX2 inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC6 citations68
US11059886B1Jul 13, 2021
Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators
FLAGSHIP PIONEERING INNOVATIONS V INC1 citations60
US11274158B2Mar 15, 2022
Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
FLAGSHIP PIONEERING INNOVATIONS V INC0 citations59
US11013717B1May 25, 2021
Methods and compositions for treating cancer using SERCA pump inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC1 citations57
EDITAS MEDICINE INC
4 patentsUS10190137B2Jan 29, 2019
CRISPR-related methods and compositions with governing gRNAS
EDITAS MEDICINE INC37 citations97
US9834791B2Dec 5, 2017
CRISPR-related methods and compositions with governing gRNAS
EDITAS MEDICINE INC97 citations97
US10640788B2May 5, 2020
CRISPR-related methods and compositions with governing gRNAs
EDITAS MEDICINE INC18 citations93
US11390887B2Jul 19, 2022
CRISPR-related methods and compositions with governing gRNAS
EDITAS MEDICINE INC6 citations85